



ASX ANNOUNCEMENT

Investor Information Sessions

MELBOURNE, Australia (20 July 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite shareholders and potential investors to attend in-person presentations in Melbourne or Sydney.

Chair, Sam Lanyon and Chief Executive Officer, Doug Ward will provide an update on the business, including the commercialisation progress on FebriDx®, following the US FDA granting of CLIA waiver on 27 March 2026.

The presentations will be followed by a Q&A session.

IN-PERSON BRIEFING OPTIONS FOR INVESTORS:

To register, please email the address below, then enter your name and contact details. Please register by close of business Monday, 27 July 2026.	
Melbourne	Wednesday, 29 July 2026, 3.15pm arrival for 3.30pm - 5.00pm William Buck, Level 20, 181 William Street, Melbourne. RSVP: ir@lumosdiagnostics.com (specify Melbourne session).
Sydney	Monday 3 August 2026, 3.00pm arrival for 3:15pm - 4.45pm Workspace 365 – Ruby Tuesday room. Level 11, 66 Clarence Street, Sydney. RSVP: ir@lumosdiagnostics.com (specify Sydney session).

The Lumos investor relations team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598